Announcement

Collapse
No announcement yet.

Kesompta vs. Ocrevus

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Kesompta vs. Ocrevus

    I am currently on Ocrevus. Does Kesimpta have any advantage s? Or is is simply a question. Of administration. I took rebif for some time so injections donít scare me. But long infusions are a hassle.

    #2
    Kesimpta a.k.a Ofatumumab is the correct name.

    Comment


      #3
      Originally posted by Brad1138 View Post
      I am currently on Ocrevus. Does Kesimpta have any advantage s? Or is is simply a question. Of administration. I took rebif for some time so injections donít scare me. But long infusions are a hassle.
      Ofatumumab was compared head to head with Aubagio can was shown to be a superior medication (on average).
      It's impossible to know if it's a better drug than Ocrelizumab, but here are a few thoughts:

      - Ocrelizumab is humanized, while Ofatumumab is fully human. This should decrease the chance of developing neutralizing antibodies. Developing neutralizing antibodies is even a bigger problem with Rituximab that is chimeric in nature. Treatment induced anti-drug antibodies (ADAs) were detected in 2 of 914 (0.2%) KESIMPTA-treated patients; no patients with treatment enhancing or neutralizing ADAs were identified.

      - a number of patients report breakthrough activity before their next 6 month Ocrelizumab infusion. These people may be experiencing early b-cell repopulation. With monthly dosing it's unlikely that b-cells would ever repopulate.

      - as you mentioned, Ofatumumab is a self-injected so infusions are no longer required. I'm a difficult IV stick so this medication would remedy that problem for me.

      - all three b-cell depleting therapies bind slightly differently to the CD20 cells so one could work better for you than the others.

      - there's recent research that shows Ocrelizumab may negate the effects of vaccines. With Rituximab and Ocrelizumab, timing can be used to try to maximize and potential benefit. With a monthly injection it could reduce the effectiveness of vaccines even further and is mentioned in the prescribing information. This could hinder the effectiveness of a covid vaccine.

      - normally Ocrelizumab is infused with steroids and other premedications. These additional medications are not necessary for Ofatumumab injections.

      - the side effect profile of each medication is different so you may tolerate one better than another. Upper respiratory infections are more likely in Ofatumumab so that could be a covid concern.

      - with 12 injections you have more opportunities for medication reactions. Many people feel side effects after Ocrelizumab infusions, but that's only twice per year. If you have injection reactions (greater than 10%) every dose you could end up with more days of recovery.

      - it's worth noting that, like Rituximab, the dosing of Ofatumumab for MS patients is much lower than for cancer patients

      - Ocrelizumab infusions of 2.5 hours have been approved in Europe and will probably be approved here in the US before long.

      Comment

      Working...
      X